Merck, through its U.S. and Canada healthcare division EMD Serono, has announced a landmark agreement with the Trump Administration to significantly expand access to in vitro fertilization (IVF) treatments for millions of Americans struggling with infertility.
Under the new public-private partnership, EMD Serono will offer direct-to-consumer (DTC) sales of its complete portfolio of IVF therapies — including Gonal-f®, Ovidrel®, and Cetrotide® — at up to 84% off list prices when used together in a typical IVF protocol. This discounted access will be available through TrumpRx.gov, a new federal platform launching in January 2026, as part of a broader initiative tied to a White House Executive Order aimed at improving fertility care access.
The announcement was made during a first-of-its-kind fertility event at the White House, where President Trump and administration officials confirmed that EMD Serono had voluntarily complied with all provisions of the Executive Order.
“This agreement is about expanding affordable access to IVF treatments and helping more families achieve their dream of having a child,” said Danny Bar-Zohar, CEO Healthcare and Executive Board Member at Merck. “We’re proud to support this national priority and continue to lead in fertility innovation.”
EMD Serono is the leading provider of fertility therapies in the U.S., with Gonal-f being the most prescribed follicle-stimulating hormone. The company’s IVF portfolio has been involved in more than 6 million successful births worldwide.
In addition to the discount initiative, EMD Serono will file Pergoveris® — a combination of recombinant FSH and LH — for review under the FDA’s National Priority Voucher (CNPV) program, which fast-tracks drug reviews aligned with national health goals. If approved, Pergoveris would be the first and only therapy of its kind available in the U.S., offering fewer injections and potentially lowering overall treatment costs.
To further align with U.S. industrial and health policy goals, Merck has also reached an agreement with the U.S. Department of Commerce to exempt its products from Section 232 tariffs, in exchange for increased biopharmaceutical investment and manufacturing in the U.S.
“We are committed to growing our presence in the U.S. and ensuring patients can benefit from the innovations in our portfolio,” said Belén Garijo, CEO of Merck. “This partnership reflects our long-term dedication to delivering access and value in fertility care.”
With 1 in 8 U.S. couples facing infertility, the Merck–U.S. government agreement marks a significant step in making advanced fertility treatments more accessible, affordable, and patient-friendly nationwide.